GLP-1 weight loss care for Mississippi, online.

Telehealth in Mississippi: where things stand

Mississippi regulates physician practice through the Mississippi State Board of Medical Licensure under Miss. Code Ann. § 73-25-1 et seq. The Board permits licensed Mississippi physicians to establish a patient relationship and issue prescriptions through telehealth encounters provided the visit meets the same standard of care as an in-person visit. Mississippi modernized its telemedicine rules under the Mississippi Telemedicine Parity Act and subsequent Board guidance, and the state allows physicians to conduct real-time audiovisual telehealth encounters that establish a valid physician-patient relationship for most non-controlled conditions.

Mississippi has the highest rate of adult obesity in the United States and among the most limited access to specialist obesity medicine outside of Jackson, Oxford, Hattiesburg, and the Gulf Coast. Residents of the Delta — Coahoma, Tunica, Sunflower, Washington counties — face some of the longest specialist travel distances and the highest rates of metabolic disease in the nation. A telehealth evaluation with a Mississippi-licensed physician through Puri removes that barrier and makes the same clinical review available to every Mississippi resident regardless of county.

Who qualifies for GLP-1 weight loss in Mississippi

Qualification for GLP-1 medication is based on clinical criteria, not geography. A licensed physician will evaluate:

• Your BMI. Most providers follow FDA prescribing guidelines for brand-name products, which typically require a BMI of 30 or greater, or 27 or greater with a weight-related health condition (such as hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea).
• Your medical history. Certain conditions contraindicate GLP-1 use, including personal or family history of medullary thyroid carcinoma or MEN2, history of pancreatitis, severe gastroparesis, active cancer, and pregnancy or breastfeeding.
• Your current medications. Some medications interact significantly with GLP-1 receptor agonists. A full medication review is part of every intake.
• Your goals and expectations. A provider wants to understand what you are hoping to achieve and whether GLP-1 therapy fits the rest of your life.

If you meet the clinical criteria and have no contraindications, a Puri-affiliated physician licensed in Mississippi may determine that compounded semaglutide or tirzepatide is appropriate. If not, they will explain why and you will not be charged for medication you did not receive.

What to expect from GLP-1 therapy

GLP-1 receptor agonists work by mimicking a hormone the body naturally produces to regulate appetite, slow gastric emptying, and improve insulin sensitivity. The result for most patients is reduced hunger, smaller portion sizes, and gradual weight loss.

Clinical trial data on the brand-name FDA-approved versions (Wegovy, Zepbound) show average weight loss of 12-18% of body weight over 12 months when combined with lifestyle changes. Compounded semaglutide and tirzepatide have not been evaluated for equivalence to brand products, so individual results may vary.

Most patients experience a slow, steady reduction in appetite and weight over the first three months. Side effects, when they occur, are usually mild gastrointestinal symptoms (nausea, constipation, decreased appetite) that improve as the body adjusts. Your provider will start you at a low dose and increase gradually to minimize side effects.

Compounded vs brand-name: what's the difference?

Brand-name semaglutide (Wegovy, Ozempic) and brand-name tirzepatide (Zepbound, Mounjaro) are FDA-approved finished drug products manufactured by Novo Nordisk and Eli Lilly. They have undergone clinical trials, FDA review, and ongoing post-market safety monitoring. They are sold at standard pharmacies and may be partially covered by insurance.

Compounded semaglutide and compounded tirzepatide are custom-prepared by state-licensed compounding pharmacies under a valid prescription. Compounded medications are NOT FDA-approved, have not been evaluated by the FDA for safety or effectiveness, and have not been reviewed for equivalence to brand-name products. The FDA permits compounding of these medications under specific conditions, but a compounded medication is not the same as a brand-name medication and should not be assumed to be identical.

Who should not take GLP-1 medication

GLP-1 medication is not appropriate for everyone. A licensed physician will decline to prescribe if any of the following apply:

• Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2).
• Personal history of pancreatitis.
• Pregnancy, breastfeeding, or actively trying to conceive.
• Active or recent cancer.
• Severe gastroparesis or other severe gastrointestinal motility disorder.
• Active eating disorder.
• Severe kidney or liver disease.
• BMI that does not meet clinical criteria for weight management medication.
• Residence outside Mississippi (we only prescribe in states where our providers are licensed).

How to get started in Mississippi

The process is straightforward:

1. 1Complete the 5-minute online intake at our assessment page.
2. 2Provide your Mississippi address and verify your residency.
3. 3Wait for physician review (typically within 24 hours).
4. 4If approved, receive your medication at your Mississippi address.
5. 5Use provider messaging for ongoing questions and dose adjustments.

Ready to begin? Start your assessment. A licensed physician eligible to practice in Mississippi will review your information and be in touch.